Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 randomized double-blind placebo-controlled study of single ascending and multiple titrated doses of TAK-935 in healthy Japanese adults
jRCT2080225253Phase 1Completed
- Sponsor
- Mistrau Bio (Note: This product was divested from Takeda Pharmaceutical Company Limited in 2026)
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of soticlestat (4 arms), sponsored by Mistrau Bio (Note: This product was divested from Takeda Pharmaceutical Company Limited in 2026). Primary endpoints: Safety and tolerability and Pharmacokinetics of TAK-935. Started Jun 2020; status: completed.
02
Drugs
soticlestat
Beyond the preview
Go deeper on jRCT2080225253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225253.